Vor Biopharma
Focus: Vor Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T stem cell therapy for hematologic malignancies and autoimmune diseases, headquartered in Cambridge, MA. The company operates in the high-value cell and gene therapy space with multiple Phase 3 programs.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
Open Jobs
17
Should You Work at Vor Biopharma?
AI assessmentStrong fit for early-career and mid-career professionals seeking deep expertise in cell therapy with meaningful clinical impact, provided you can tolerate binary regulatory risk.
Why Work Here
- Leading position in cutting-edge CAR-T stem cell therapy, a next-generation modality with significant clinical and commercial potential.
- Multiple Phase 3 programs across high-unmet-need indications (SLE, Sjögren's, myasthenia gravis, AML) positioned for near-term regulatory catalysts.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT05309733A Long-term Follow-up Study of Patients Who Received VOR33
N/AHelp build intelligence for Vor Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.